News and Trends 24 Apr 2023 Life Biosciences gene therapy data shows visual function restored in primates Life Biosciences (Life Bio) has announced preclinical data in nonhuman primates (NHP) for its novel gene therapy candidate, which uses a partial epigenetic reprogramming approach to restore visual function. The approach has been shown to reverse aging, improve vision, and extend lifespan in mice, but whether epigenetic reprogramming would work in primates was not known. […] April 24, 2023 - 4 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 21 Apr 2023 New discovery “an area of cancer research with tremendous promise for breakthroughs” A research team led by Gary Ying Wai Chan from the School of Biological Sciences at The University of Hong Kong (HKU), has revealed the function of a unique enzyme, ANKLE1. ANKLE1 acts on chromatin bridges trapped in the midzone of dividing cells. By cutting these bridges, ANKLE1 prevents damage to the genetic material and […] April 21, 2023 - 4 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 21 Apr 2023 RetinAI and Boehringer Ingelheim to use AI to develop treatment for geographic atrophy RetinAI Medical AG, which creates clinical and imaging data management software and advanced analytics using artificial intelligence (AI) for ophthalmology, is partnering with Boehringer Ingelheim. The companies aim to improve patient outcomes in geographic atrophy (GA) by combining RetinAI’s Discovery platform and AI tools with Boehringer Ingelheim’s research in retinal diseases. GA is a progressive, […] April 21, 2023 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 21 Apr 2023 Orphalan announces U.S. launch of drug to treat Wilson disease Orphalan SA, an international orphan drug development and commercialization company, has announced the commercial launch in the U.S. for Cuvrior. Cuvrior is a new trientine tetrahydrochloride (TETA-4HCl). It is now available for the treatment of adult patients with stable Wilson disease who are de-coppered and tolerant to D-penicillamine. Cuvrior was approved by the United States […] April 21, 2023 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 21 Apr 2023 Can artificial intelligence predict future pandemics? Before the first cases of COVID-19 became known, an algorithm based on artificial intelligence developed by a company in Canada had already detected a new virus spreading across the Chinese city of Wuhan. This demonstration of the potential of new technologies applied to predicting future epidemics led a group of researchers at the Universitat Oberta […] April 21, 2023 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 20 Apr 2023 FDA approves Genentech’s lymphoma drug Genentech, a member of the Roche Group, has announced the U.S. Food and Drug Administration (FDA) has approved Polivy (polatuzumab vedotin-piiq) in combination with Rituxan (rituximab), cyclophosphamide, doxorubicin and prednisone (R-CHP). The approval covers the treatment of adult patients who have previously untreated diffuse large B-cell lymphoma (DLBCL), not otherwise specified (NOS) or high-grade B-cell […] April 20, 2023 - 4 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 20 Apr 2023 Hasten raises $315M for acquisitions and pipeline development CBC Group, Asia’s largest healthcare-dedicated investment firm headquartered in Singapore, and Hasten Biopharmaceutic Company Limited, have completed a $315 million fundraising round for Hasten. Hasten is a Chinese biopharma company backed by CBC, Hefei Industry Investment Group, and Feidong County of Hefei City. The fundraising round was co-led by CBC and Abu Dhabi sovereign wealth […] April 20, 2023 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 19 Apr 2023 Wound treatment boost from new color-changing dressing A nanocellulose wound dressing that can reveal early signs of infection without interfering with the healing process has been developed by researchers at Linköping University, Sweden. The study, published in Materials Today Bio, is another step on the road to a new type of wound care. The skin is the largest organ of the human […] April 19, 2023 - 5 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 19 Apr 2023 Forbion raises €1.35B to invest in life science companies European life sciences venture capital firm Forbion has raised €1.35 billion ($1.5 billion) for its two newest funds, bringing the total of funds under management to €3 billion ($3.3 billion). Both funds exceeded the original target sizes and represent Forbion’s largest fundraising to date. The final close of the Forbion Ventures Fund VI has reached […] April 19, 2023 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 19 Apr 2023 Nanocages developed to deliver small interfering RNAs Small interfering RNAs (siRNAs) are novel therapeutics that can be used to treat a wide range of diseases. This has led to a growing demand for selective, efficient, and safe ways of delivering siRNA in cells. Now, in a cooperation between the universities of Amsterdam and Leiden in the Netherlands, researchers have developed dedicated molecular […] April 19, 2023 - 4 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 18 Apr 2023 Complement Therapeutics raises €72M for eye condition gene therapy Complement Therapeutics GmbH (CTx), a preclinical stage biotechnology company developing novel therapeutics for complement mediated diseases, has completed a €72 million ($78.7 million) Series A financing. The round was led by Gimv, a Belgian-based private equity and venture capital fund, co-led by Forbion as existing investor and further joined by BioGeneration Ventures (BGV), Panakes Partners, […] April 18, 2023 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 17 Apr 2023 Swedish bacterial resistance study could pave road to new antibiotics A species of ordinary gut bacteria flourishes when the intestinal flora is knocked out by a course of antibiotics. Since the bacteria are naturally resistant to many antibiotics, this can cause problems. A study at Lund University in Sweden now shows how two molecular mechanisms can work together to make the bacterium extra resistant. “Using […] April 17, 2023 - 4 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email